UNSPSC 51112035: Osimertinib

Osimertinib is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

UNSPSC 51112035 Osimertinib is a Commodity code that nominally covers a specific cancer treatment medication, yet the recent state and local opportunities posted under this code show little relevant activity. The posted records include a departmental relocation notice from Williamson County, Texas with no procurement scope; a trade show announcement; vendor forum notices; and a nursing survey—none of which relate to pharmaceutical procurement or osimertinib distribution. One opportunity (Seminole County's naloxone procurement) involves pharmaceutical products but addresses opioid-reversal agents, not oncology medications, and appears misclassified under this code. The source does not identify any issuing bodies actively soliciting osimertinib or comparable cancer medications under this code in recent months.

Given the sparse and largely unrelated recent activity, this code does not show current procurement momentum for osimertinib or related pharmaceutical commodities at the state and local level. No geographic concentration, repeat buyer pattern, or representative recent opportunity can be credibly established from the available records. Practitioners evaluating this code should verify whether state and local health departments, pharmacy benefit managers, or hospital networks are posting osimertinib contracts under alternative UNSPSC codes or procurement vehicles before committing significant pursuit resources.